177Lu-PSMA-I&T Radioligand Therapy for Treating Metastatic Castration-Resistant Prostate Cancer: A Single-Centre Study in East Asians
PurposeThere is increasing evidence for convincing efficacy and safety of 177Lu-labled prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (PRLT) for metastatic castration-resistant prostate cancer (mCRPC). However, data are not available regarding the feasibility of 177Lu-labled...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-03-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.835956/full |
| _version_ | 1818307827975847936 |
|---|---|
| author | Ting Bu Lulu Zhang Fei Yu Xiaochen Yao Wenyu Wu Pengjun Zhang Liang Shi Shiming Zang Qingle Meng Yudan Ni Guoqiang Shao Xuefeng Qiu Shuyue Ai Ruipeng Jia Hongqian Guo Feng Wang |
| author_facet | Ting Bu Lulu Zhang Fei Yu Xiaochen Yao Wenyu Wu Pengjun Zhang Liang Shi Shiming Zang Qingle Meng Yudan Ni Guoqiang Shao Xuefeng Qiu Shuyue Ai Ruipeng Jia Hongqian Guo Feng Wang |
| author_sort | Ting Bu |
| collection | DOAJ |
| description | PurposeThere is increasing evidence for convincing efficacy and safety of 177Lu-labled prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (PRLT) for metastatic castration-resistant prostate cancer (mCRPC). However, data are not available regarding the feasibility of 177Lu-labled PSMA-targeted RLT in East Asians. The present study summarized the first experience with 177Lu-PSMA-I&T therapy for mCRPC in China.MethodsForty consecutive patients with mCRPC were enrolled from December 2019 to September 2021. Eligible patients received 177Lu-PSMA-I&T RLT at intervals of 8-12 weeks. Toxicity was assessed based on standardized physicians’ reports and the Common Toxicity Criteria for Adverse Events criteria. Response to PRLT was evaluated according to the changes of prostate specific antigen (PSA) response and imaging response. Quality of life (QOL), Karnofsky performance status (KPS) and pain (visual analogue scale, VAS) were also evaluated. The impacts of baseline parameters on the therapeutic effects were explored by univariate and multivariate logistic regression analyses.ResultsAll patients underwent a total of 86 cycles of 177Lu-PSMA-I&T (range: 1-5 cycles) with dosages of 3.70-14.43GBq per cycle, with a median of 8 months followed up. Six patients (15%) developed mild reversible xerostomia during follow-up, and 28 patients (70%) experienced grade 1-4 bone marrow dysfunction. Changes in PSA were assessed after therapy, accompanied by the partial response (PR) in 25 patients (62.5%), the stable disease (SD) in 5 patients (12.5%), and the progressive disease (PD) in 10 patients (25%), respectively. QOL, KPS (%) and VAS scores were improved significantly due to treatment (P<0.05). Overweight and elevated AST, ALP, and LDH were associated with poor outcomes.Conclusions177Lu-PSMA-I&T achieves the favourable response and well tolerance in mCRPC, which associates with not only PSA decline but also with tumor remission including lymphadenopathy and bone metastasis. We also find that patients with overweight and high AST, ALP, and LDH should be cautious to undergo the PRLT. Large-cohort studies are warranted to confirm the initial findings and elucidate the survival benefit of the treatment. |
| first_indexed | 2024-12-13T07:04:34Z |
| format | Article |
| id | doaj.art-7be87c94ac634be1a2f3e9f9a3237150 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-13T07:04:34Z |
| publishDate | 2022-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-7be87c94ac634be1a2f3e9f9a32371502022-12-21T23:55:51ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-03-011210.3389/fonc.2022.835956835956177Lu-PSMA-I&T Radioligand Therapy for Treating Metastatic Castration-Resistant Prostate Cancer: A Single-Centre Study in East AsiansTing Bu0Lulu Zhang1Fei Yu2Xiaochen Yao3Wenyu Wu4Pengjun Zhang5Liang Shi6Shiming Zang7Qingle Meng8Yudan Ni9Guoqiang Shao10Xuefeng Qiu11Shuyue Ai12Ruipeng Jia13Hongqian Guo14Feng Wang15Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, ChinaDepartment of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, ChinaDepartment of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, ChinaDepartment of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, ChinaDepartment of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, ChinaDepartment of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, ChinaDepartment of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, ChinaDepartment of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, ChinaDepartment of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, ChinaDepartment of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, ChinaDepartment of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, ChinaDepartment of Urology, Nanjing Drum Hospital, Nanjing University, Nanjing, ChinaDepartment of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, ChinaDepartment of Urology, Nanjing First Hospital, Nanjing Medical University, Nanjing, ChinaDepartment of Urology, Nanjing Drum Hospital, Nanjing University, Nanjing, ChinaDepartment of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, ChinaPurposeThere is increasing evidence for convincing efficacy and safety of 177Lu-labled prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (PRLT) for metastatic castration-resistant prostate cancer (mCRPC). However, data are not available regarding the feasibility of 177Lu-labled PSMA-targeted RLT in East Asians. The present study summarized the first experience with 177Lu-PSMA-I&T therapy for mCRPC in China.MethodsForty consecutive patients with mCRPC were enrolled from December 2019 to September 2021. Eligible patients received 177Lu-PSMA-I&T RLT at intervals of 8-12 weeks. Toxicity was assessed based on standardized physicians’ reports and the Common Toxicity Criteria for Adverse Events criteria. Response to PRLT was evaluated according to the changes of prostate specific antigen (PSA) response and imaging response. Quality of life (QOL), Karnofsky performance status (KPS) and pain (visual analogue scale, VAS) were also evaluated. The impacts of baseline parameters on the therapeutic effects were explored by univariate and multivariate logistic regression analyses.ResultsAll patients underwent a total of 86 cycles of 177Lu-PSMA-I&T (range: 1-5 cycles) with dosages of 3.70-14.43GBq per cycle, with a median of 8 months followed up. Six patients (15%) developed mild reversible xerostomia during follow-up, and 28 patients (70%) experienced grade 1-4 bone marrow dysfunction. Changes in PSA were assessed after therapy, accompanied by the partial response (PR) in 25 patients (62.5%), the stable disease (SD) in 5 patients (12.5%), and the progressive disease (PD) in 10 patients (25%), respectively. QOL, KPS (%) and VAS scores were improved significantly due to treatment (P<0.05). Overweight and elevated AST, ALP, and LDH were associated with poor outcomes.Conclusions177Lu-PSMA-I&T achieves the favourable response and well tolerance in mCRPC, which associates with not only PSA decline but also with tumor remission including lymphadenopathy and bone metastasis. We also find that patients with overweight and high AST, ALP, and LDH should be cautious to undergo the PRLT. Large-cohort studies are warranted to confirm the initial findings and elucidate the survival benefit of the treatment.https://www.frontiersin.org/articles/10.3389/fonc.2022.835956/full177Luprostate cancermetastatic castration-resistant prostate cancer (mCRPC)prostate-specific membrane antigen (PSMA)radioligand therapy (RLT) |
| spellingShingle | Ting Bu Lulu Zhang Fei Yu Xiaochen Yao Wenyu Wu Pengjun Zhang Liang Shi Shiming Zang Qingle Meng Yudan Ni Guoqiang Shao Xuefeng Qiu Shuyue Ai Ruipeng Jia Hongqian Guo Feng Wang 177Lu-PSMA-I&T Radioligand Therapy for Treating Metastatic Castration-Resistant Prostate Cancer: A Single-Centre Study in East Asians Frontiers in Oncology 177Lu prostate cancer metastatic castration-resistant prostate cancer (mCRPC) prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) |
| title | 177Lu-PSMA-I&T Radioligand Therapy for Treating Metastatic Castration-Resistant Prostate Cancer: A Single-Centre Study in East Asians |
| title_full | 177Lu-PSMA-I&T Radioligand Therapy for Treating Metastatic Castration-Resistant Prostate Cancer: A Single-Centre Study in East Asians |
| title_fullStr | 177Lu-PSMA-I&T Radioligand Therapy for Treating Metastatic Castration-Resistant Prostate Cancer: A Single-Centre Study in East Asians |
| title_full_unstemmed | 177Lu-PSMA-I&T Radioligand Therapy for Treating Metastatic Castration-Resistant Prostate Cancer: A Single-Centre Study in East Asians |
| title_short | 177Lu-PSMA-I&T Radioligand Therapy for Treating Metastatic Castration-Resistant Prostate Cancer: A Single-Centre Study in East Asians |
| title_sort | 177lu psma i t radioligand therapy for treating metastatic castration resistant prostate cancer a single centre study in east asians |
| topic | 177Lu prostate cancer metastatic castration-resistant prostate cancer (mCRPC) prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.835956/full |
| work_keys_str_mv | AT tingbu 177lupsmaitradioligandtherapyfortreatingmetastaticcastrationresistantprostatecancerasinglecentrestudyineastasians AT luluzhang 177lupsmaitradioligandtherapyfortreatingmetastaticcastrationresistantprostatecancerasinglecentrestudyineastasians AT feiyu 177lupsmaitradioligandtherapyfortreatingmetastaticcastrationresistantprostatecancerasinglecentrestudyineastasians AT xiaochenyao 177lupsmaitradioligandtherapyfortreatingmetastaticcastrationresistantprostatecancerasinglecentrestudyineastasians AT wenyuwu 177lupsmaitradioligandtherapyfortreatingmetastaticcastrationresistantprostatecancerasinglecentrestudyineastasians AT pengjunzhang 177lupsmaitradioligandtherapyfortreatingmetastaticcastrationresistantprostatecancerasinglecentrestudyineastasians AT liangshi 177lupsmaitradioligandtherapyfortreatingmetastaticcastrationresistantprostatecancerasinglecentrestudyineastasians AT shimingzang 177lupsmaitradioligandtherapyfortreatingmetastaticcastrationresistantprostatecancerasinglecentrestudyineastasians AT qinglemeng 177lupsmaitradioligandtherapyfortreatingmetastaticcastrationresistantprostatecancerasinglecentrestudyineastasians AT yudanni 177lupsmaitradioligandtherapyfortreatingmetastaticcastrationresistantprostatecancerasinglecentrestudyineastasians AT guoqiangshao 177lupsmaitradioligandtherapyfortreatingmetastaticcastrationresistantprostatecancerasinglecentrestudyineastasians AT xuefengqiu 177lupsmaitradioligandtherapyfortreatingmetastaticcastrationresistantprostatecancerasinglecentrestudyineastasians AT shuyueai 177lupsmaitradioligandtherapyfortreatingmetastaticcastrationresistantprostatecancerasinglecentrestudyineastasians AT ruipengjia 177lupsmaitradioligandtherapyfortreatingmetastaticcastrationresistantprostatecancerasinglecentrestudyineastasians AT hongqianguo 177lupsmaitradioligandtherapyfortreatingmetastaticcastrationresistantprostatecancerasinglecentrestudyineastasians AT fengwang 177lupsmaitradioligandtherapyfortreatingmetastaticcastrationresistantprostatecancerasinglecentrestudyineastasians |